TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01732380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltitrexed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Study: NCT05489146

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial random noise stimulation and functional electrical stimulation facilitated task practice
Description: Participants were randomized to one of the two intervention groups \[transcranial current stimulation (tRNS) and functional electrical stimulation (FES) or FES with sham tRNS\] before pre-intervention testing. After randomization, participants underwent pre-intervention testing, followed by intervention 3 times per week for 6 weeks. Each intervention session lasted for 1 hour, where tRNS or sham-tRNS were delivered concurrently with the FES-facilitated task practice. tRNS or sham-tRNS was delivered for the first 30 minutes. Both tRNS and sham tRNS were delivered by the Starstim system. FES was delivered using the Neuromove system. All participants were treated by a licensed occupational therapist, who was trained on a manualized protocol.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial random noise stimulation and functional electrical stimulation facilitated task practice
Description: Participants were randomized to one of the two intervention groups \[transcranial current stimulation (tRNS) and functional electrical stimulation (FES) or FES with sham tRNS\] before pre-intervention testing. After randomization, participants underwent pre-intervention testing, followed by intervention 3 times per week for 6 weeks. Each intervention session lasted for 1 hour, where tRNS or sham-tRNS were delivered concurrently with the FES-facilitated task practice. tRNS or sham-tRNS was delivered for the first 30 minutes. Both tRNS and sham tRNS were delivered by the Starstim system. FES was delivered using the Neuromove system. All participants were treated by a licensed occupational therapist, who was trained on a manualized protocol.
Study: NCT04489511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STG-001
Description: Dose 1 or Dose 2 of STG-001 will be administered daily for 28 days to compare safety, pharmacokinetics and pharmacodynamics in Stargardt disease subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STG-001
Description: Dose 1 or Dose 2 of STG-001 will be administered daily for 28 days to compare safety, pharmacokinetics and pharmacodynamics in Stargardt disease subjects.
Study: NCT00915291

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based educational modules
Description: Interactive case-based modules that includes video vignettes of clinical interactions between hypothetical patients interacting with physicians
Study: NCT03576716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D6-25-hydroxyvitamin D3
Description: Intravenous administration of a deuterium-labeled 25(OH)D3 to evaluate the metabolic clearance of 25(OH)D3
Study: NCT02136628

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Method RTL
Description: The method consists of two lines of suture, each, over the fascial wound edge. It starts with a suture strand (in this study was used PDS number 0) in one end of the fascial wound where the suture is run longitudinally and parallel to the aponeurotic edge. The needle should go in and out at intervals of 1 cm away and always kept at 0.5 cm from the edge of the fascia. Upon reaching the opposite angle of the wound suture strand another repeating the same process on the fascial edge otherwise used. The ends of the two suture strands are tied in fascial angles.~Thus the fascial wound is sutured with two lines of strengthening its edges. Then proceed to close the wound with continuous súrgete always ensuring that the suture lines remain anchored on suture reinforcement.
Study: NCT03851055

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zinc
Description: One arm will receive Zinc Second arm will receive placebo
Study: NCT01618149

Intervention type: RADIATION
Intervention: dual energy x-ray absorptiometry
Description: before the surgery of total knee arthroplasty and after the surgery 6 months and 12 months
Study: NCT02188849

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Description: All participants will be subjected to resistance training of upper and lower limbs, using elastic bands and tubing and free weights. Training will be calibrated at 60% of one repetition maximum for each muscle group with three sets of 15 repetitions with one minute rest between each set. All exercises will be additionally calibrated to be of moderate intensity according to the Borg scale. The exercise load will be adapted according to the progression of each participant.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Resistance exercise training
Description: All participants will be subjected to resistance training of upper and lower limbs, using elastic bands and tubing and free weights. Training will be calibrated at 60% of one repetition maximum for each muscle group with three sets of 15 repetitions with one minute rest between each set. All exercises will be additionally calibrated to be of moderate intensity according to the Borg scale. The exercise load will be adapted according to the progression of each participant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Creatine
Description: Creatine powder 5 g day
Study: NCT05229029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCM Formula
Description: TCM herbs：White peony 10g, angelica 10g, Astragalus 20g, Atractylodes macrocephala 10g, tangerine peel 6g, Poria cocos 10g, raw land 10g, cinnamon 3g, Polygala tenuifolia 6g, Schisandra chinensis 6g, raw licorice 6g.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mainly made of dextrin and caramel, containing 1/30 concentration of experimental group drugs
Study: NCT00317096

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FCM
Description: Active comparator: Chemotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: R-FCM
Description: experimental: Chemotherapy with additional rituximab

Intervention type: DRUG
Group type: OTHER
Intervention: rituximab maintenance
Description: 2 courses of rituximab maintenance after completion of salvage therapy

Intervention type: OTHER
Group type: OTHER
Intervention: observation only
Description: no Intervention after completion of FCM or R-FCM
Study: NCT04241302

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pure Tone Audiogram
Description: A Pure Tone Audiogram is done in a sound proof room in both cases of Free Field Voice Test and Free Field Click Tests to identify the Pure Tone Average (Hearing Threshold Average of 500Hz,1000Hz and 2000Hz).

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pure Tone Audiogram
Description: A Pure Tone Audiogram is done in a sound proof room in both cases of Free Field Voice Test and Free Field Click Tests to identify the Pure Tone Average (Hearing Threshold Average of 500Hz,1000Hz and 2000Hz).
Study: NCT00346229

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lyso-thermosensitive liposomal doxorubicin(Thermodox)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hyperthermia treatment
Study: NCT02658136

Intervention type: OTHER
Group type: OTHER
Intervention: Cardiac Computed tomography
Study: NCT00625677

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeisVacC (Meningococcal C conjugate vaccine)
Description: Dosage

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menjugate (Meningococcal C conjugate vaccine)
Description: Dosage
Study: NCT03726008

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perinatal health promotion program and regular prenatal care
Description: Regular prenatal care and perinatal health promotion program including health promotion during pregnant period, health promotion during the ritual of Tso-Yueh-Tzu, health promotion during postpartum period, newborn care
Study: NCT04001283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitrite
Description: Intravenous drug infusion
Study: NCT00914472

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: heparin sodium - APP
Description: Heparin 5000 IU / mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Heparin sodium - Hipolabor
Description: Heparin 5000 IU / mL
Study: NCT02779166

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04001283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitrite
Description: Intravenous drug infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium-chloride
Description: Matched placebo
Study: NCT04132596

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous spinal cord stimulation
Description: Electrical stimulation of the spinal cord via transcutaneous hydrogel electrodes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous spinal cord stimulation
Description: Electrical stimulation of the spinal cord via transcutaneous hydrogel electrodes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous spinal cord stimulation
Description: Electrical stimulation of the spinal cord via transcutaneous hydrogel electrodes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activity Based Therapy
Description: Physical therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activity Based Therapy
Description: Physical therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activity Based Therapy
Description: Physical therapy
Study: NCT03190616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib
Description: apatinib 500mg/qd, 28d/cycle
Study: NCT02518191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRHa
Description: 3.6mg subcutaneous injection every 28 days.Initiated 1-2 weeks before chemotherapy and ended 4-8 weeks after chemotherapy.
Study: NCT03100773

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral health educational strategy
Description: Oral health educational strategy consisted of four consecutive sessions (once a week) about etiological factors of caries (using visual aids), oral hygiene instructions (using models), supervised toothbrushing and explanation of atraumatic restorative treatment (indications and stages).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral health educational strategy
Description: Oral health educational strategy consisted of four consecutive sessions (once a week) about etiological factors of caries (using visual aids), oral hygiene instructions (using models), supervised toothbrushing and explanation of atraumatic restorative treatment (indications and stages).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atraumatic Restorative Treatment
Description: Atraumatic Restorative Treatment was performed using hand instruments for opening and cleaning the cavities and a high-viscosity glass-ionomer for restoration.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atraumatic Restorative Treatment
Description: Atraumatic Restorative Treatment was performed using hand instruments for opening and cleaning the cavities and a high-viscosity glass-ionomer for restoration.
Study: NCT04879173

Intervention type: DEVICE
Intervention: RS85 Ultrasound device
Description: RS85 Ultrasound device manufactured by Samsung Medison

Intervention type: DEVICE
Intervention: RS85 Ultrasound device
Description: RS85 Ultrasound device manufactured by Samsung Medison
Study: NCT00615173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus (FK506)
Description: Started: 0.05-0.1mg/kg/d,divided into two daily dose at 12hr; the blood level:5-10ng/ml in induction phase;and 4-6ng/ml in maintenance phase;

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide or azathioprine
Description: Induction phase: CTX 0.75g/m2 monthly Maintenance phase: AZA 2mg/kg/d.
Study: NCT01949610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-JNJ26489112
Description: Participants will receive single dose of oral suspension of 1000 mg (10 mL) of 14C-JNJ26489112 on Day 1.
Study: NCT03012204

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: real LFrTMS at unaffected M1
Description: Compare the effect of LFrTMS at unaffected M1 to that of all sham stimulation on motor rehabilitation after cerebrovascular disease .~rTMS: Repetitive Transcranial Magnetic Stimulation. Combination Elements: ①6 hertz(Hz) rTMS at unaffected M1 before LFrTMS at unaffected M1 ;②6 Hz rTMS at affected M1;③1 Hz rTMS at unaffected M1.~The four groups are the combinations of real or sham ①/②/③.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real primed LFrTMS at unaffected M1
Description: Compare the effect of primed LFrTMS at unaffected M1 to that of LFrTMS at unaffected M1 on motor rehabilitation after cerebrovascular disease .~rTMS: Repetitive Transcranial Magnetic Stimulation. Combination Elements: ①6 hertz(Hz) rTMS at unaffected M1 before LFrTMS at unaffected M1 ;②6 Hz rTMS at affected M1;③1 Hz rTMS at unaffected M1.~The four groups are the combinations of real or sham ①/②/③.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: combined rTMS at both M1
Description: Compare the effect of combined rTMS at both M1 to that of primed LFrTMS at unaffected M1 on motor rehabilitation after cerebrovascular disease .~rTMS: Repetitive Transcranial Magnetic Stimulation. Combination Elements: ①6 hertz(Hz) rTMS at unaffected M1 before LFrTMS at unaffected M1 ;②6 Hz rTMS at affected M1;③1 Hz rTMS at unaffected M1.~The four groups are the combinations of real or sham ①/②/③.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: all sham stimulation
Description: used as controls to eliminate the placebo effect of all kinds of combinated rTMS
Study: NCT01965691

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein intake
Description: Oral consumption of eight hourly experimental meals-~* 4 tracer free experimental meals containing a mixture of free amino acids and calories from protein free flavored liquid, protein free cookies and corn oil~* 4 isotopically labeled experimental meals.
Study: NCT02434640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1128688
Description: Part A: Single dose and multiple dose for 14 days (postmenopausal women)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1128688
Description: Part A: Single dose and multiple dose for 14 days (postmenopausal women)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1128688
Description: Part A: Single dose and multiple dose for 14 days (postmenopausal women)
Study: NCT02598388

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Description: One 0.5 mL IM injection of (1x10\*8 infectious units).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One 0.5 mL IM injection of 0.9 percent (%) saline.
Study: NCT02434640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1128688
Description: Part A: Single dose and multiple dose for 14 days (postmenopausal women)
Study: NCT01298765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEMA Buprenorphine
Description: buccal soluble film; applied to the buccal mucosa twice daily
Study: NCT01124591

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention
Description: two session delivered two weeks apart
Study: NCT01094548

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tecemotide (L-BLP25)
Description: After receiving single low dose of cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 806 microgram (mcg) of tecemotide (L-BLP25) at Weeks 1, 2, 3, 4, 5, 6, 7 and 8 followed by maintenance vaccinations (806 mcg of tecemotide (L-BLP25) at 6-Week intervals, commencing at Week 14, until disease progression requiring anti-tumor therapy is documented.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tecemotide (L-BLP25)
Description: After receiving multiple low dose of cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 806 mcg of tecemotide (L-BLP25) at Weeks 1, 2, 3, 4, 5, 6, 7 and 8 followed by maintenance vaccinations (806 mcg of tecemotide (L-BLP25) at 6-Week intervals, commencing at Week 14, until disease progression requiring anti-tumor therapy is documented.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single low dose cyclophosphamide
Description: An intravenous (IV) infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first vaccine treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple low dose cyclophosphamide
Description: An IV infusion of 300 mg/m\^2 (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first vaccine treatment plus an intravenous dose of cyclophosphamide (300 mg/m\^2, to a maximum of 600 mg) 3 days prior to the tecemotide (LBLP25) administration at week 5 of the weekly treatment phase and 3 days prior to every tecemotide (L-BLP25) administration during the treatment phase with 6-Weekly administration of tecemotide (L-BLP25), commencing at Week 14 up to a maximum treatment period of 2 years.
Study: NCT02869594

Intervention type: OTHER
Intervention: Data collection
Study: NCT01874496

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GDS, no meal
Description: GDS, no meal

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GDS, meal
Description: GDS, meal

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: control, no meal
Description: control, no meal

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: control, meal
Description: control, meal
Study: NCT00481546

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: rAAV2-CBSB-hRPE65
Description: One or two, uniocular, subretinal injections; relative doses: 0.3X (Cohort 1), 0.6X (Cohort 2), 0.45X (Cohort 3), 0.9X (Cohorts 4 and 5)
Study: NCT02434640

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part A: Single dose and multiple dose for 14 days (postmenopausal women)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1128688
Description: Part B: Multiple dose for 28 days (premenopausal women)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1128688
Description: Part B: Multiple dose for 28 days (premenopausal women)
Study: NCT03654638

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: The dietary intervention requires men to consume 2 slices soy bread each day for 20 weeks while initiating hormone therapy

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Intervention
Description: The dietary intervention requires men to consume 2 slices wheat bread each day for 20 weeks while initiating hormone therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01071772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin
Description: There will be used individual intravenous insulin (actrapid) infusion to prevent non-intended hyperglycemia.
Study: NCT01408121

Intervention type: OTHER
Intervention: Genotyping and platelet reactivity testing with the VerifyNow P2Y12 assay
Description: All patients will undergo genotyping and platelet reactivity testing with the VerifyNow P2Y12 assay, at least 6 hours after receiving a thienopyridine loading dose but before hospital discharge.

Intervention type: OTHER
Intervention: Genotyping and platelet reactivity testing with the VerifyNow P2Y12 assay
Description: All patients will undergo genotyping and platelet reactivity testing with the VerifyNow P2Y12 assay, at least 6 hours after receiving a thienopyridine loading dose but before hospital discharge.

Intervention type: OTHER
Intervention: Genotyping and platelet reactivity testing with the VerifyNow P2Y12 assay
Description: All patients will undergo genotyping and platelet reactivity testing with the VerifyNow P2Y12 assay, at least 6 hours after receiving a thienopyridine loading dose but before hospital discharge.

Intervention type: OTHER
Intervention: Genotyping and platelet reactivity testing with the VerifyNow P2Y12 assay
Description: All patients will undergo genotyping and platelet reactivity testing with the VerifyNow P2Y12 assay, at least 6 hours after receiving a thienopyridine loading dose but before hospital discharge.
Study: NCT02562651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Doxycycline bid for the first 7 days after primary anterior STEMI

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care for STEMI
Description: Invasive and medical treatment for STEMI according to guidelines
Study: NCT02800083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitolisant (BF2.649)
Study: NCT01632202

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Seprafilm
Description: Seprafilm Adhesion Barrier (membrane) is a sterile, bioresorbable, translucent adhesion barrier composed of two anionic polysaccharides, sodium hyaluronate (HA) and carboxymethylcellulose (CMC). Together, these biopolymers have been chemically modified with the activating agent 1-(3-dimethylaminopropyl) -3- ethylcarbodiimide hydrochloride (EDC).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Saline Solution
Description: For those randomized not to receive Seprafilm slurry, a syringe will be filled with 25ml of sterile saline.
Study: NCT01986868

Intervention type: OTHER
Group type: OTHER
Intervention: Coronary MR Angiography (CMRA)
Description: Stable patients who have undergone a clinically indicated CCTA study for suspected Coronary Artery Disease will undergo a research CMRA with contrast (Multihance or Optimark)total dose of up to 0.2 mmol/kg IV. Possible administration of oral beta-blocker (metoprolol)intravenous doses of 5mg IV metoprolol may be given every 2 minutes up to a maximal dose of 15 mg IV.